Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rabeprazole sodium (Habeprazole Sodium) 是一种质子泵抑制剂,不可逆地抑制胃 H+/K+-ATPase,可研究胃溃疡和胃食管反流。它诱导细胞凋亡,也抑制尿苷核苷核糖水解酶 ,IC50为 0.3 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 413 | 现货 | ||
25 mg | ¥ 618 | 现货 | ||
50 mg | ¥ 763 | 现货 | ||
100 mg | ¥ 1,120 | 现货 | ||
200 mg | ¥ 1,670 | 现货 | ||
500 mg | ¥ 2,820 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells. |
靶点活性 | UNH:0.3 μM (IC50) |
体外活性 | Administration of rabeprazole leads to a marked decrease in the viability of MKN-28 cells. Exposure to rabeprazole induces significant apoptosis in AGS cells. Rabeprazole completely inhibits the phosphorylation of ERK 1/2 in the MKN-28 cells, whereas the same effect is not observed in either the KATO III or MKN-45 cells. Rabeprazole is able to efficaciously inhibit the phosphorylation of ERK 1/2 in the gastric cancer cells.Thus, rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 signaling pathway[2]. |
体内活性 | Rabeprazole does not appear to exacerbate bone metabolic disorders in gastrectomized rats, but rather ameliorates the TG-induced BMD decrease[1]. |
细胞实验 | Rabeprazole is administrated to three gastric cancer cell lines, KATO III, MKN-28 and MKN-45, at a dosage of 0.2 mM for 16 h. The viability of these cells is determined by a trypan blue exclusion assay.(Only for Reference) |
别名 | Dexrabeprazole Sodium, LY307640 sodium, Habeprazole Sodium, 雷贝拉唑钠, Rebeprazole sodium, Aciphex Sodium |
分子量 | 381.42 |
分子式 | C18H20N3NaO3S |
CAS No. | 117976-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 71 mg/mL (186.1 mM)
H2O: 1.34mg/mL(3.5mM), Sonification is recommended
Ethanol: 71 mg/mL (186.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O / Ethanol | 1 mM | 2.6218 mL | 13.1089 mL | 26.2178 mL | 65.5445 mL |
DMSO / Ethanol | 5 mM | 0.5244 mL | 2.6218 mL | 5.2436 mL | 13.1089 mL |
10 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL | 6.5545 mL | |
20 mM | 0.1311 mL | 0.6554 mL | 1.3109 mL | 3.2772 mL | |
50 mM | 0.0524 mL | 0.2622 mL | 0.5244 mL | 1.3109 mL | |
100 mM | 0.0262 mL | 0.1311 mL | 0.2622 mL | 0.6554 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rabeprazole sodium 117976-90-6 Apoptosis Membrane transporter/Ion channel Proton pump ATPase Dexrabeprazole Sodium LY 307640 ulcerations gastric LY307640 sodium LY307640 UNH Habeprazole Sodium PPI inhibit pump 雷贝拉唑钠 proton Proton Pump reflux uridine Rebeprazole sodium Rabeprazole LY-307640 nucleoside ribohydrolase Inhibitor gastroesophageal Aciphex Sodium inhibitor